Company Overview: NTLA

Upcoming Projects (NTLA)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (NTLA)

Examining the Phase 1 data of Intellia's NTLA-2001 and outcomes data from the phase 3 attribute-cm trial of BridgeBio's acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Tickers: NTLA, BBIO
Executed On: Nov 22, 2023 at 09:00 AM EST
A Second Look: Investigating Intellia’s CRISPR therapy NTLA-2002 in development for the treatment of swelling attacks in hereditary angioedema (HAE).
Ticker: NTLA
Executed On: Jul 06, 2023 at 05:00 PM EDT
Investigating Intellia’s CRISPR therapy NTLA-2002 in development for the treatment of swelling attacks in hereditary angioedema (HAE).
Ticker: NTLA
Executed On: Jun 27, 2023 at 02:00 PM EDT

Expired Projects (NTLA)

An in-depth look at the Gene Therapy Landscape
Tickers: VRTX, BLUE, ONCE, CRSP, EDIT, NTLA
Execute By: Dec 31, 2021

Upcoming & Overdue Catalysts (NTLA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (NTLA)

Intellia's (NTLA) presented interim data in ongoing Phase 1 trial of NTLA-2001 Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Ticker: NTLA
Occurred on: Jun 26, 2021
Intellia Therapeutics (NTLA) shows first demonstration of physiological protein levels of human alpha-1 antitrypsin (AAT) in non-human primates (NHPs) following a single administration
Ticker: NTLA
Occurred on: Dec 12, 2020
Between second half 2017 and first half 2018, Intellia Therapeutics (NTLA) will start initial new drug application-based (IND) studies on Transtherytin Amyloidosis (ATTR), a gene-editing therapy using from CRISPR/Cas9 gene revision concept
Tickers: NTLA, CRSP, BAYRY
Occurred on: Oct 18, 2018
Intellia Therapeutics (NTLA) set to commence non-human primate (NHP) studies on Transtherytin Amyloidosis (ATTR), a gene-editing therapy developed with Regeneron based on the CRISPR/Cas9 genetic editing system in 2017
Tickers: NTLA, CRSP, BAYRY, REGN
Occurred on: May 01, 2018
NTLA in vivo Hepatitis B Virus (HBV) program by Intellia, based on CRISPR/Cas9 genetic editing system, set for HBV animal trials in 2017
Tickers: NTLA, BAYRY, CRSP
Occurred on: May 01, 2018
Intellia (NTLA) Granted European Patent Covering CRISPR/Cas9 Genome Editing Technology
Ticker: NTLA
Occurred on: Apr 11, 2017
Intellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components
Ticker: NTLA
Occurred on: Aug 18, 2016
Intellia Therapeutics Announces Pricing of Initial Public Offering
Ticker: NTLA
Occurred on: May 05, 2016

Strategic Initiatives (NTLA)

Don’t see a strategic initiative related to the company you care about? Create your own!

NTLA Overview